MENU

Identification of Novel Protein Biomarkers in the Era of Precision Medicine Oncology

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Cancer is a leading cause of morbidity and mortality in developed countries including the United States. Early detection of various cancers, before they spread and become incurable, has been the best weapon in the war on cancer that began with the signing of the National Cancer Act in 1971. The premise of Precision Medicine is the ability to customize personalized medical care to individual patients through the incorporation of molecular profiles and clinical characteristics in treatment determination utilizing molecular diagnostics, and targeted therapies.

Proteins uniquely produced by tumors and their surrounding microenvironment constitute valuable biomarkers that aid in diagnosis of initial tumors, screening the population, monitoring of tumor progression, metastases, response to treatment and relapse (e.g., the prostate-specific antigen, PSA, is routinely used for screening and monitoring of prostate cancer). Moreover, some biomarkers can stratify patients into sub-groups that differ in their prognosis and response to different treatment options, which allows designing individual treatment plans. For instance, the human epidermal growth factor receptor 2 (Her2-neu) is overexpressed in about 20% of breast cancer patients and can be targeted by a monoclonal antibody called Herceptin in these patients, which enhances the overall survival when combined with chemotherapy.

Recent advances in Genomics and Proteomics allow for the de-novo identification of tumor-related biomarkers through differential expression analyses of the different steps of cancer progression. In our approach to biomarker discovery, we combine the techniques of laser capture microdissection, differential two- dimensional gel electrophoresis, and mass spectrometry to identify novel biomarkers of tumor progression for cervical cancer and other malignancies. These identified molecular markers have promising clinical utility in Precision Medicine Oncology.

Learning Objectives: 

1. Explain the role of Proteomics in Cancer Molecular Diagnostics.
2. Describe the experimental design behind the de-novo biomarker discovery approach combining laser capture microdissection, differential two- dimensional gel electrophoresis, and mass spectrometry to identify novel biomarkers of tumor progression.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
OCT 27, 2021 6:00 AM PDT
C.E. CREDITS
OCT 27, 2021 6:00 AM PDT
Date: October 27, 2021 Time: 6:00 AM PDT, 9:00 AM EDT Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such...
OCT 12, 2021 9:00 AM PDT
C.E. CREDITS
OCT 12, 2021 9:00 AM PDT
Date: October 12, 2021 Time: 9:00am (PDT), 12:00pm (EDT) SCIEX’s next-generation Biologics Explorer software is an innovative platform for the comprehensive and deep characterization o...
SEP 09, 2021 8:00 AM PDT
C.E. CREDITS
SEP 09, 2021 8:00 AM PDT
Date: September 09, 2021 Time: 8:00am (PDT), 11:00am (EDT) Human pluripotent stem cells (PSCs) hold great potentials in regenerative therapies. In this webinar, Chao will first present the c...
Loading Comments...
Show Resources
Event Countdown
  • 0 Days
  • 0 Hours
  • 0 Minutes
  • 0 Seconds